Bradykinin Or Derivative Patents (Class 514/12.5)
-
Patent number: 10292387Abstract: A tick removal ointment which is a topical composition having 25% benzocaine incorporated in white petroleum jelly. The amount of benzocaine in the tick removal ointment is efficacious for numbing the tick and hence causes the tick to release or self-extricate from the host mammal, optimally prior to the transmission of disease organisms from the tick to the host mammal. Upon the self-extrication of the tick from the host mammal, the white petroleum jelly is efficacious for killing the tick. Application of the present tick removal ointment eliminates the need to make direct contact with the tick to remove the tick and further eliminates the task of observing the mammal for a ii period of time because the composition is devised to first release the tick from the host mammal and then to kill the tick once the tick is released from the host mammal.Type: GrantFiled: October 31, 2016Date of Patent: May 21, 2019Inventor: James Dill
-
Patent number: 9212206Abstract: The present invention has multiple aspects. In its first aspect, it is directed to a compound that is a 4(S)-fluoro-thio-tripeptide analog that has the unexpectedly superior property of specifically inhibiting the enzyme, membrane-bound aminopeptidase P2 (APP2), whose natural substrate is bradykinin, but not the enzyme angiotensin converting enzyme (ACE) which also cleaves bradykinin. In its second aspect, the present invention is directed to a pharmaceutical composition comprising the 4(S)-fluoro-thio-tripeptide analog and a pharmaceutically acceptable carrier. In its third aspect, the invention is directed to a method of inhibiting bradykinin degradation in a mammalian patient, comprising administering a therapeutically effective amount of the compound of the invention to a mammalian patient in need of inhibition of bradykinin degradation.Type: GrantFiled: November 24, 2014Date of Patent: December 15, 2015Inventor: William H Simmons
-
Patent number: 8883153Abstract: One aspect of the present invention provides a method of treating or preventing angioedema in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R. One aspect of the present invention provides a method of treating or preventing vascular permeability in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R.Type: GrantFiled: March 29, 2010Date of Patent: November 11, 2014Assignee: The Research for The State University of New YorkInventor: Berhane Ghebrehiwet
-
Publication number: 20140242153Abstract: Disclosed are novel methods for making cochleates and cochleate compositions that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compositions that include an aggregation inhibitor, and optionally, a cargo moiety. Additionally, anhydrous cochleates that include a protonized cargo moiety, a divalent metal cation and a negatively charge lipid are disclosed. Methods of using the cochleate compositions of the invention, including methods of administration, are also disclosed.Type: ApplicationFiled: January 30, 2014Publication date: August 28, 2014Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Raphael J. Mannino, Susan Gould-Fogerite, Sara L. Krause-Elsmore, David Delmarre, Ruying Lu
-
Publication number: 20130136717Abstract: The present invention relates to bradykinin receptor modulators and pharmaceutical compositions thereof for use as a medicament for modulating collateral blood vessel growth of collateral arteries and/or other blood vessels of pre-existing arterial networks. The bradykinin receptor modulators of arteriogenesis are applicable in the treatment and/or prevention of disorders associated with defective blood flow or blood vessel malformation. A preferred aspect of the invention relates to bradykinin receptor agonists for use as a medicament for the prevention of cardiovascular ischemic disease in a patient at risk thereof. Further, the invention relates to a bradykinin receptor agonist for use in a method for treating a cardiovascular ischemic disease in a patient in need thereof, wherein said cardiovascular ischemic disease is a peripheral limb disease.Type: ApplicationFiled: May 16, 2011Publication date: May 30, 2013Applicant: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZINInventors: Philipp Hillmeister, Ivo Buschmann, Ferdinand Lenoble, Nora Gatzke
-
Patent number: 8288351Abstract: The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a univalent vehicle, including peptides conjugated to univalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.Type: GrantFiled: April 8, 2008Date of Patent: October 16, 2012Assignee: Amgen Inc.Inventors: Gordon Ng, Yue-Sheng Li, Colin V. Gegg, Benny C. Askew, Jr., Thomas Storz, Yuelie Lu, Derin C. D'Amico, Mark A. Jarosinski, Chuan-Fa Liu, Qi Huang
-
Patent number: 8278280Abstract: The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.Type: GrantFiled: April 8, 2008Date of Patent: October 2, 2012Assignee: Amgen Inc.Inventors: Gordon Ng, Yue-Sheng Li, Colin V. Gegg, Benny C. Askew, Jr., Thomas Storz, Yuelie Lu, Derin C. D'Amico, Mark A. Jarosinski, Chuan-Fa Liu, Qi Huang
-
Patent number: 8263555Abstract: The invention provides methods for treating and/or preventing ocular disorders associated with increased intraocular pressure comprising administering a bradykinin B2 receptor agonist to a patient in need thereof.Type: GrantFiled: August 24, 2010Date of Patent: September 11, 2012Assignee: Alcon Research, Ltd.Inventor: Najam A. Sharif
-
Publication number: 20120195932Abstract: The present invention provides geodate delivery vehicles and methods of manufacture and administration. A vehicle including a lipid monolayer disposed about a hydrophobic domain is disclosed, that can be part of an emulsion or other mixture, or further disposed in a lipid strata. A vehicle including a lipid strata disposed about a hydrophobic domain is also disclosed. The vehicle can be incorporated into a variety of medicinal, food preparations, and personal care products to deliver or stabilize a cargo moiety. Packaged delivery vehicles for to later addition of cargo moieties are also contemplated.Type: ApplicationFiled: January 25, 2010Publication date: August 2, 2012Applicant: BioDelivery Sciences International, Inc.Inventors: Raphael J. Mannino, Sara L. Krause-Elsmore, Susan Gould-Fogerite, David Delmarre, Ruying Lu
-
Publication number: 20120129774Abstract: The present invention provides for novel kinin B1 receptors peptide agonists of formula (1) having very good to excellent affinities and selectivity for the B1 receptor, in vitro and in vivo increased resistance to enzymatic degradation, superior pharmacokinetic properties to those of naturally occurring agents, capacity to significantly enhance delivery of chemotherapeutic substances across the blood brain barrier and within peripheral tissues for the treatment of tumors, capacity to protect and restore kidney, heart, brain and other organ functions, when given alone or in combination with other therapies in the treatment of hypertension, diabetes and other cardiovascular diseases particularly, but not limited to, atherosclerosis and arteriosclerosis.Type: ApplicationFiled: November 11, 2011Publication date: May 24, 2012Inventors: Fernand GOBEIL, Witold A. NEUGEBAUER, Domenico REGOLI, David FORTIN
-
Publication number: 20120045430Abstract: Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. The nucleic acids are used to form dendrimers that are useful as supports, vectors, carriers or delivery vehicles for a variety of compounds in biomedical and biotechnological applications. In particular, the macromolecules may be used for the delivery of drugs, genetic material, imaging components or other functional molecule to which they can be conjugated. An additional feature of the macromolecules is their ability to be targeted for certain organs, tumors, or types of tissues. Methods of utilizing such biomaterials include delivery of functional molecules to cells.Type: ApplicationFiled: August 15, 2011Publication date: February 23, 2012Inventors: Dan Luo, Yougen Li
-
Patent number: 7932228Abstract: Provided is a method for the use of a bradykinin B1 receptor antagonist of formula I: X-CO-Aaa0-Aaa1-Aaa2-Aaa3-Gly-?(Me)Phe-Ser-D-?Nal-Aaa8-OH (I) or a pharmaceutically acceptable salt or hydrate thereof wherein: X is CnH2n+1 or CiH2i—C6H5, where n is an integer from 1 to 3, and i is an integer from 0 to 3; Aaa0 is Lys, Orn or Cit; Aaa1 is Arg or Cit, and preferably Arg; Aaa2 is Oic, Hyp or Pro, and preferably Oic; Aaa3 is Pro or Oic, and preferably Pro; and Aaa8 is Ile, Leu or Nle, and preferably Ile, for the treatment of metastases, cancers and/or chemotherapy-induced neuropathies, comprising the administration of the compound to a patient in need of such treatment. Also provided are compositions containing such antagonists and their thereof.Type: GrantFiled: June 12, 2006Date of Patent: April 26, 2011Assignee: Societe de Commercialisation des Produits de la Recherche Applique Socpra Sciences Sante et Humaines S.E.C.Inventors: François Nantel, Roger Chammas, Pierre Sirois, Bruno Joseph Battistini
-
Publication number: 20110009322Abstract: The invention provides methods for treating and/or preventing ocular disorders associated with increased intraocular pressure comprising administering a bradykinin B2 receptor agonist to a patient in need thereof.Type: ApplicationFiled: August 24, 2010Publication date: January 13, 2011Applicant: ALCON RESEARCH, LTD.Inventor: Najam A. SHARIF
-
Publication number: 20100297066Abstract: Novel biodegradable compositions are disclosed. The biodegradable compositions include at least one hydroxyl-terminated component and at least one bioactive peptide in a linear chain. The compositions may be utilized as medical devices including drug delivery devices, tissue adhesives and/or sealants.Type: ApplicationFiled: May 14, 2008Publication date: November 25, 2010Inventors: Joshua B. Stopek, Brian Cuevas
-
Publication number: 20100254939Abstract: The present invention relates to graft copolymers of polyvinyl sulfonic-co-vinyl alcohol)-g-poly(lactide-co-glycolide) (P(VS-VA)-g-PLGA) with negatively charged electrolyte properties, their method of preparation and their use. These negatively charged graft copolymers are suitable for effective loading and sustained-release of especially positively charged drugs, proteins and peptides, and drug-loaded particles from these grafted co-polymers are especially useful as parenteral or mucosal drug delivery systems for pharmaceutical applications.Type: ApplicationFiled: September 8, 2008Publication date: October 7, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Thomas Kissel, Xiaoying Wang